14 results on '"Inagaki, Yosuke"'
Search Results
2. Isolation of rugosin A, B and related compounds as dipeptidyl peptidase-IV inhibitors from rose bud extract powder
- Author
-
Kato, Eisuke, Uenishi, Yuta, Inagaki, Yosuke, Kurokawa, Mihoko, and Kawabata, Jun
- Abstract
Dipeptidyl peptidase-IV (DPP-IV) is a protease responsible for the degradation of the incretin hormone. A number of DPP-IV inhibitors have been approved for use in the treatment of type 2 diabetes. While these inhibitors are effective for this treatment, methods for the prevention of this disease are also required as diabetes patient numbers are currently increasing rapidly worldwide. We screened the DPP-IV inhibitory activities of edible plant extracts with the intention of using these extracts in a functional food supplement for the prevention of diabetes. Rose (Rosa gallica) bud extract powder was a promising material with high inhibitory activity. In this study, seven ellagitannins were isolated as active compounds through activity-guided fractionations, and their DPP-IV inhibitory activities were measured. Among them, rugosin A and B showed the highest inhibitory activities and rugosin B was shown as the major contributing compound in rose bud extract powder.
- Published
- 2016
- Full Text
- View/download PDF
3. Advanced Glycation End‐Products Attenuate Human Mesenchymal Stem Cells and Prevent Cognate Differentiation Into Adipose Tissue, Cartilage, and Bone
- Author
-
Kume, Shinichiro, Kato, Seiya, Yamagishi, Sho‐ichi, Inagaki, Yosuke, Ueda, Seiji, Arima, Nobuyuki, Okawa, Takahiro, Kojiro, Masamichi, and Nagata, Kensei
- Abstract
The impact of AGEs on human MSCs was studied. AGEs inhibited the proliferation of MSCs, induced apoptosis, and prevented cognate differentiation into adipose tissue, cartilage, and bone, suggesting a deleterious effect of AGEs in the pathogenesis of musculoskeletal disorders in aged and diabetic patients.
- Published
- 2005
- Full Text
- View/download PDF
4. Advanced Glycation End‐Products Attenuate Human Mesenchymal Stem Cells and Prevent Cognate Differentiation Into Adipose Tissue, Cartilage, and Bone1*
- Author
-
Kume, Shinichiro, Kato, Seiya, Yamagishi, Sho‐ichi, Inagaki, Yosuke, Ueda, Seiji, Arima, Nobuyuki, Okawa, Takahiro, Kojiro, Masamichi, and Nagata, Kensei
- Abstract
The impact of AGEs on human MSCs was studied. AGEs inhibited the proliferation of MSCs, induced apoptosis, and prevented cognate differentiation into adipose tissue, cartilage, and bone, suggesting a deleterious effect of AGEs in the pathogenesis of musculoskeletal disorders in aged and diabetic patients.Introduction: Advanced glycation end‐products (AGEs) are accumulated on long‐lived proteins of various tissues in advanced age and diabetes mellitus and have been implicated in chronic complication, including musculoskeletal disorders. Human mesenchymal stem cells (MSCs) potentially differentiate into mature musculoskeletal tissues during tissue repair, but the pathogenetic role of AGEs on MSCs is unclear.Materials and Methods: AGEs were prepared by incubating BSA with glucose, glyceraldehydes, or glycolaldehyde (designated as AGE‐1, AGE‐2, or AGE‐3, respectively). Proliferation, apoptosis, and reactive oxygen species (ROS) generation were assayed in AGE‐treated cells. The expression of the receptor for AGE (RAGE) was examined by immunohistochemistry and Western blotting. Involvement of RAGE‐mediated signaling was examined using a neutralizing antiserum against RAGE. Differentiation into adipose tissue, cartilage, and bone were morphologically and biochemically monitored with specific markers for each.Results: AGE‐2 and AGE‐3, but not control nonglycated BSA and AGE‐1, reduced the viable cell number and 5‐bromo‐2'deoxyuridine (BrdU) incorporation with increased intracellular ROS generation and the percentage of apoptotic cells. MSCs expressed RAGE and its induction was stimulated by AGE‐2 and AGE‐3. These AGEs inhibited adipogenic differentiation (assayed by oil red O staining, lipoprotein lipase production, and intracellular triglyceride content) and chondrogenic differentiation (assayed by safranin O staining and type II collagen production). On osteogenic differentiation, AGE‐2 and AGE‐3 increased alkaline phosphatase activity and intracellular calcium content; however, von Kossa staining revealed the loss of mineralization and mature bone nodule formation. The antiserum against RAGE partially prevented AGE‐induced cellular events.Conclusion: AGE‐2 and AGE‐3 may lead to the in vivo loss of MSC mass and the delay of tissue repair by inhibiting the maturation of MSC‐derived cells. The AGE‐RAGE interaction may be involved in the deleterious effect of AGEs on MSCs.
- Published
- 2005
- Full Text
- View/download PDF
5. Minodronate, a Newly Developed Nitrogen-Containing Bisphosphonate, Suppresses Melanoma Growth and Improves Survival in Nude Mice by Blocking Vascular Endothelial Growth Factor Signaling
- Author
-
Yamagishi, Sho-ichi, Abe, Riichiro, Inagaki, Yosuke, Nakamura, Kazuo, Sugawara, Hiroshi, Inokuma, Daisuke, Nakamura, Hideki, Shimizu, Tadamichi, Takeuchi, Masayoshi, Yoshimura, Akihiko, Bucala, Richard, Shimizu, Hiroshi, and Imaizumi, Tsutomu
- Abstract
Angiogenesis, a process by which new vascular networks are formed from pre-existing capillaries, is required for tumors to grow, invade, and metastasize. Vascular endothelial growth factor (VEGF), a specific mitogen to endothelial cells, is a crucial factor for tumor angiogenesis. In this study, we investigated whether minodronate, a newly developed nitrogen-containing bisphosphonate, could inhibit melanoma growth and improve survival in nude mice by suppressing the VEGF signaling. We found here that minodronate inhibited melanoma growth and improved survival in nude mice by suppressing the tumor-associated angiogenesis and macrophage infiltration. Minodronate completely inhibited the VEGF-induced increase in DNA synthesis and tube formation in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation and Ras activation. Furthermore, minodronate inhibited the VEGF-induced expression of intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in endothelial cells. Minodronate decreased DNA synthesis and increased apoptotic cell death of cultured melanoma cells as well. Our present study suggests that minodronate might suppress melanoma growth and improve survival in nude mice by two independent mechanisms; one is by blocking the VEGF signaling in endothelial cells, and the other is by inducing apoptotic cell death of melanoma. The present study provides a novel potential therapeutic strategy for the treatment of melanoma.
- Published
- 2004
- Full Text
- View/download PDF
6. Azelnidipine, A Newly Developed Long-Acting Calcium Antagonist, Inhibits Tumor Necrosis Factor--Induced Interleukin-8 Expression in Endothelial Cells through its Anti-Oxidative Properties
- Author
-
Yamagishi, Sho-ichi, Inagaki, Yosuke, Nakamura, Kazuo, and Imaizumi, Tsutomu
- Abstract
Interleukin-8 (IL-8), a member of CXC chemokine family, has been found to play an important role in the pathogenesis of atherosclerosis. Tumor necrosis factor- (TNF-) is involved in the development and progression of atherosclerosis as well. In this study, we investigated whether and how azelnidipine, a newly developed long-acting calcium antagonist, could inhibit TNF--induced IL-8 expression in human umbilical vein endothelial cells (HUVEC). TNF- significantly increased intracellular reactive oxygen species (ROS) generation in HUVEC, which was completely blocked by azelnidipine or apocynin, an inhibitor of NADPH oxidase. Azelnidipine also completely prevented TNF-–induced increase in NADPH oxidase activity in HUVEC. Further, azelnidipine was found to significantly inhibit activator protein-1 (AP-1) promoter activity and IL-8 expression in TNF--exposed HUVEC. An inhibitor of AP-1, curcumin, or an anti-oxidant, N-acetylcysteine, also inhibited the TNF--induced IL-8 expression in HUVEC. These results demonstrated that azelnidipine inhibited TNF--induced IL-8 expression in HUVEC by blocking NADPH oxidase-mediated ROS generation and subsequent AP-1 activation. Our present study suggests that azelnidipine may play a protective role in the development and progression of atherosclerosis through its anti-oxidative properties.
- Published
- 2004
7. Overexpression of Pigment Epithelium-Derived Factor Decreases Angiogenesis and Inhibits the Growth of Human Malignant Melanoma Cells in Vivo
- Author
-
Abe, Riichiro, Shimizu, Tadamichi, Yamagishi, Sho-ichi, Shibaki, Akihiko, Amano, Shinjiro, Inagaki, Yosuke, Watanabe, Hirokazu, Sugawara, Hiroshi, Nakamura, Hideki, Takeuchi, Masayoshi, Imaizumi, Tsutomu, and Shimizu, Hiroshi
- Abstract
Pigment epithelium-derived factor (PEDF) has recently been shown to be the most potent inhibitor of angiogenesis in the mammalian eye, and is involved in the pathogenesis of angiogenic eye disease such as proliferative diabetic retinopathy. However, a functional role for PEDF in tumor growth and angiogenesis remains to be determined. In this study, we have investigated both the in vitroand in vivogrowth characteristics of human malignant melanoma G361 cell lines, stably transfected to overexpress human PEDF. Expression levels of PEDF proteins in melanoma cell lines G361 and A375 were comparable with that of human cultured melanocytes, whereas vascular endothelial growth factor levels in two tumor cell lines were much stronger than that in normal melanocytes. Overexpression of PEDF was found to significantly inhibit tumor growth and vessel formation in G361 nude mice xenografts. Furthermore, in vitroproliferation rates of G361 cells were decreased in PEDF-transfected cells. PEDF proteins showed dose-dependent induced growth retardation and apoptotic cell death in nontransfected G361 cells, which were completely prevented by treatment with antibodies against the Fas ligand. Our present study highlights two beneficial effects of PEDF treatment on melanoma growth and expansion; one is the suppression of tumor angiogenesis, and the other is induction of Fas ligand-dependent apoptosis in tumor cells. PEDF therefore might be a promising novel therapeutic agent for treatment of patients with melanoma.
- Published
- 2004
- Full Text
- View/download PDF
8. CS-866, a New Angiotensin II Type 1 Receptor Antagonist, Ameliorates Glomerular Anionic Site Loss and Prevents Progression of Diabetic Nephropathy in Otsuka Long-Evans Tokushima Fatty Rats
- Author
-
Koga, Kohachiro, Yamagishi, Sho-ichi, Takeuchi, Masayoshi, Inagaki, Yosuke, Amano, Shinjiro, Okamoto, Tamami, Saga, Tsuyoshi, Makita, Zenji, and Yoshizuka, Mitsuaki
- Abstract
Background: Diabetic nephropathy is a leading cause of end-stage renal disease in industrialized countries. Previous studies have documented that angiotensin converting enzyme (ACE) inhibitors consistently reduce albuminuria and retard the progression of diabetic nephropathy. However, the involvement of angiotensin II in diabetic nephropathy is not fully understood. Materials and Methods: In this study we compared the effects of CS-866, a new angiotensin II type 1 receptor antagonist, to that of an ACE inhibitor, temocapril hydrochloride, on the development and progression of diabetic nephropathy using Otsuka Long-Evans Tokushima fatty rats, a type II diabetes mellitus model animal. Results: High doses of CS-866 or temocapril treatment were found to significantly improve urinary protein and β
2 -microglobulin excretions in diabetic rats. In electron microscopic analysis, loss of glomerular anionic sites, one of the causes of glomerular hyperpermeability in diabetic nephropathy, was found to be significantly prevented by CS-866 treatment. Light microscopic examinations revealed that both treatments ameliorated glomerular sclerosis and tubulointerstitial injury in diabetic rats. Furthermore, high doses of CS-866 or temocapril treatment significantly reduced the positive stainings for transforming growth factor-β(TGF-β), vascular endothelial growth factor, and type IV collagen in glomeruli of diabetic rats. Conclusions: These results indicate that intrarenal angiotensin II type 1 receptor activation plays a dominant role in the development and progression of diabetic nephropathy. Our study suggests that CS-866 represents a valuable new drug for the treatment of diabetic patients with nephropathy.- Published
- 2002
- Full Text
- View/download PDF
9. Beraprost Sodium, a Prostaglandin I2Analogue, Protects Against Advanced Glycation End Products-induced Injury in Cultured Retinal Pericytes
- Author
-
Yamagishi, Sho-ichi, Amano, Shinjiro, Inagaki, Yosuke, Okamoto, Tamami, Takeuchi, Masayoshi, and Makita, Zenji
- Abstract
Background: Beraprost sodium, a prostaglandin I2 analogue, has been recently reported to exhibit beneficial effects on atherosclerosis in patients with diabetes. However, effects of beraprost sodium on microvascular injury in diabetes remain to be elucidated. We have previously shown that advanced glycation end products (AGE), senescent macroproteins formed at an accelerated rate in diabetes, caused pericyte apoptosis, thus being involved in the pathogenesis of the early phase of diabetic retinopathy. In this study, we examined whether beraprost sodium can protect against AGE-induced cytotoxicity in cultured retinal pericytes. Materials and Methods: Intracellular formation of reactive oxygen species (ROS) was detected using a fluorescent probe. DNA synthesis was determined by measuring [3H]thymidine incorporation into cells. Apoptosis was determined by DNA fragmentations, which were quantitatively measured in an enzyme-linked immunosorbent assay. Results: Beraprost sodium or forskolin, a stimulator of adenylate cyclase, was found to significantly inhibit AGE-induced ROS generation and the subsequent decrease in DNA synthesis in pericytes. Both treatments significantly prevented AGE-induced apoptotic cell death in pericytes. Furthermore, beraprost sodium was found to down-regulate AGE receptor mRNA levels in pericytes. Results: The results demonstrated that cyclic AMP-elevating agents such as beraprost sodium and forskolin protected retinal pericytes from AGE-induced cytotoxicity through its anti-oxidative properties. Our present study suggests that beraprost sodium may have therapeutic potentials in treatment of patients with early diabetic retinopathy.
- Published
- 2002
- Full Text
- View/download PDF
10. Advanced Glycation End Product-induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor and Monocyte Chemoattractant Protein-1 in Human-cultured Mesangial Cells*
- Author
-
Yamagishi, Sho-ichi, Inagaki, Yosuke, Okamoto, Tamami, Amano, Shinjiro, Koga, Kohachiro, Takeuchi, Masayoshi, and Makita, Zenji
- Abstract
Advanced glycation end products (AGE) have been implicated in the pathogenesis of glomerulosclerosis in diabetes. However, their involvement in the development of the early phase of diabetic nephropathy has not been fully elucidated. We investigated the effects of AGE on growth and on vascular endothelial growth factor (VEGF) and monocyte chemoattractant protein-1 (MCP-1) expression in human cultured mesangial cells. We prepared three immunochemically distinct AGE by incubating bovine serum albumin (BSA) with glucose, glyceraldehyde, or glycolaldehyde. When human mesangial cells were cultured with various types of AGE-BSA, viable cell numbers as well as DNA syntheses were significantly decreased. All of the AGE-BSA were found to significantly increase p53 and Bax protein accumulations and subsequently induce apoptotic cell death in mesangial cells. An antioxidant, N-acetylcysteine, significantly prevented the AGE-induced apoptotic cell death in mesangial cells. Human mesangial cells stimulated prostacyclin production by co-cultured glomerular endothelial cells. Furthermore, various types of AGE-BSA were found to up-regulate the levels of mRNAs for VEGFand stimulate the secretion of VEGF and MCP-1 proteins in mesangial cells. The results suggest that AGE disturbed glomerular homeostasis by inducing apoptotic cell death in mesangial cells and elicited hyperfiltration and microalbuminuria by stimulating the secretion of VEGF and MCP-1 proteins, thereby being involved in the pathogenesis of the early phase of diabetic nephropathy.
- Published
- 2002
- Full Text
- View/download PDF
11. Palmitate-Induced Apoptosis of Microvascular Endothelial Cells and Pericytes
- Author
-
Yamagishi, Sho-ichi, Okamoto, Tamami, Amano, Shinjiro, Inagaki, Yosuke, Koga, Kohachiro, Koga, Mari, Choei, Hiroshi, Sasaki, Nobuyuki, Kikuchi, Seiji, Takeuchi, Masayoshi, and Makita, Zenji
- Abstract
Background: Recent observations in the EURODIAB Complications Study demonstrated that markers of insulin resistance are strong risk factors for retinopathy incidence in patients with diabetes. However, the molecular mechanism underlying this remains to be elucidated. In this study, we investigated the influence of palmitate, a major saturated free fatty acid in plasma, on the apoptotic cell death of cultured microvascular endothelial cells (EC) and retinal pericytes. Materials and Methods: The intracellular formation of reactive oxygen species (ROS) was detected using the fluorescent probe CM-H
2 DCFDA. DNA synthesis was determined by measuring [3 H]-thymidine incorporation into cells. DNA fragmentations of EC were quantitatively analyzed in an enzyme-linked immunosorbent assay, and DNA laddering was evaluated on agarose gel electrophoresis. Results: Palmitate increased ROS generation in microvascular EC. Furthermore, palmitate significantly inhibited DNA synthesis and induced apoptotic cell death in EC, which were completely prevented by an antioxidant, N-acetylcysteine. Palmitate up-regulated pericyte mRNA levels of a receptor for advanced glycation end products (AGE), and thereby potentiated the apoptotic effects of AGE on pericytes. Conclusions: The results suggest that palmitate could induce apoptotic cell death in microvascular EC and pericytes through the overgeneration of intracellular ROS, and thus be involved in the development of diabetic retinopathy.- Published
- 2002
- Full Text
- View/download PDF
12. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin
- Author
-
Okamoto, Tamami, Yamagishi, Sho‐ichi, Inagaki, Yosuke, Amano, Shinjiro, Koga, Kohachiro, Abe, Riichiro, Takeuchi, Masayoshi, Ohno, Shigeaki, Yoshimura, Akihiko, and Makita, Zenji
- Abstract
We previously have found that advanced glycation end products (AGE), senescent macroproteins formed at an accelerated rate in diabetes, arise in vivonot only from glucose but also from reducing sugars. Furthermore, we recently have shown that glyceraldehyde‐ and glycolaldehyde‐derived AGE (glycer‐ and glycol‐AGE) are mainly involved in loss of pericytes, the earliest histopathological hallmark of diabetic retinopathy. However, the effects of these AGE proteins on angiogenesis, another vascular derangement in diabetic retinopathy, remain to be elucidated. In this study, we investigated whether these AGE proteins elicit changes in cultured endothelial cells that are associated with angiogenesis. When human skin microvascular endothelial cells (EC) were cultured with glycer‐AGE or glycol‐AGE, growth and tube formation of EC, the key steps of angiogenesis, were significantly stimulated. The AGE‐induced growth stimulation was significantly enhanced in AGE receptor (RAGE)‐overexpressed EC. Furthermore, AGE increased transcriptional activity of nuclear factor‐κB (NF‐κB) and activator protein‐1 (AP‐1) and then up‐regulated mRNA levels of vascular endothelial growth factor (VEGF) and angiopoietin‐2 (Ang‐2) in EC. Cerivastatin, a hydroxymethylglutaryl CoA reductase inhibitor; pyrrolidinedithiocarbamate; or curcumin was found to completely prevent the AGE‐induced increase in NF–κB and AP‐1 activity, VEGF mRNA up‐regulation, and the resultant increase in DNA synthesis in microvascular EC. These results suggest that the AGE‐RAGE interaction elicited angiogenesis through the transcriptional activation of the VEGF gene via NF‐κB and AP‐1 factors. By blocking AGE‐RAGE signaling pathways, cerivastatin might be a promising remedy for treating patients with proliferative diabetic retinopathy.
- Published
- 2002
- Full Text
- View/download PDF
13. Neurotoxicity of Acetaldehyde-Derived Advanced Glycation End Products for Cultured Cortical Neurons
- Author
-
TAKEUCHI, MASAYOSHI, WATAI, TAKAYUKI, SASAKI, NOBUYUKI, CHOEI, HIROSHI, IWAKI, MINA, ASHIZAWA, TAKESHI, INAGAKI, YOSUKE, YAMAGISHI, SHO-ICHI, KIKUCHI, SEIJI, RIEDERER, PETER, SAITO, TOSHIKAZU, BUCALA, RICHARD, and KAMEDA, YUKIHIKO
- Abstract
The Maillard reaction that leads to the formation of advanced glycation end products (AGEs) plays an important role in the pathogenesis of angiopathy in diabetic patients, in aging, and in neurodegenerative processes. We hypothesize that acetaldehyde (AA), one of the main metabolites of alcohol, may be involved in alcohol-induced neurotoxicity in vivo by formation of AA-derived AGEs (AA-AGEs) with brain proteins. Incubation of cortical neurons with AA-AGE produced a dose-dependent increase in neuronal cell-death, and the neurotoxicity of AA-AGE was neutralized by the addition of an anti-AA-AGE-specific antibody, but not by anti-N-ethyllysine (NEL) antibody. The AA-AGE epitope was detected in human brain of alcoholism. We propose that the structural epitope AA-AGE is an important toxic moiety for neuronal cells in alcoholism.
- Published
- 2003
- Full Text
- View/download PDF
14. Flexible Adiabatic Light Guide of Silicon Rubber
- Author
-
Fukui, Shuji, Ohska, Tokio, Ueno, Koji, Inagaki, Yosuke, Sasaki, Atsushi, Iwata, Seigi, Kusumegi, Asao, Mishina, Masanori, Miyachi, Takashi, Sato, Isamu, and Ukai, Kumataro
- Abstract
A certain type of silicon rubber (KE103RTV) is found to be a useful material as an adiabatic light guide for scintillation counters because of its mechanical flexibility. The refractive index of KE103RTV is measured to be 1.410±0.006. The transmission and the resolution of scintillation light pulses through it are comarable with those through acrylic resin light guides. This RTV has the resistivity against high dose of radiation.
- Published
- 1971
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.